{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T10:51:51Z","timestamp":1788605511184,"version":"build-2803163510"},"reference-count":32,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2022,12,20]]},"DOI":"10.18632\/oncotarget.28331","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T13:42:05Z","timestamp":1671543725000},"page":"1359-1368","source":"Crossref","is-referenced-by-count":5,"title":["Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model"],"prefix":"10.18632","volume":"13","author":[{"given":"Hirofumi","family":"Tsuzuki","sequence":"first","affiliation":[{"name":"Immuno-Oncology, Astellas Pharma Inc., Tsukuba, Ibaraki 305-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Kawase","sequence":"additional","affiliation":[{"name":"Immuno-Oncology, Astellas Pharma Inc., Tsukuba, Ibaraki 305-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisuke","family":"Nakazawa","sequence":"additional","affiliation":[{"name":"Immuno-Oncology, Astellas Pharma Inc., Tsukuba, Ibaraki 305-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamichi","family":"Mori","sequence":"additional","affiliation":[{"name":"Applied Research and Operations, Astellas Pharma Inc., Tsukuba, Ibaraki 305-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Immuno-Oncology, Astellas Pharma Inc., Tsukuba, Ibaraki 305-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2022,12,20]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.3390\/cancers12113225","article-title":"Advances in Acute Myeloid Leukemia: Recently Approved Therapies and Drugs in Development","volume":"1","author":"Taylor","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"7","author":"Jemal","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood-2015-07-604538","article-title":"Emerging therapeutic drugs for AML","volume":"12","author":"Tallman","year":"2016","journal-title":"Blood"},{"key":"4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13000-019-0841-1","article-title":"BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia","volume":"1","author":"Qian","year":"2019","journal-title":"Diagn Pathol"},{"key":"5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/sj.leu.2400557","article-title":"Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells","volume":"1","author":"Bhalla","year":"1997","journal-title":"Leukemia"},{"key":"6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"38","author":"Leber","year":"2020","journal-title":"N Engl J Med"},{"key":"7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.20517\/cdr.2020.95","article-title":"Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia","volume":"4","author":"Kaufmann","year":"2021","journal-title":"Cancer Drug Resist"},{"key":"8","article-title":"Cronin KA SEER Cancer Statistics Review, 1975-2015","author":"Feuer","year":"2018","journal-title":"National Cancer Institute"},{"key":"9","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.3390\/molecules25204764","article-title":"Antibody-Drug Conjugates for Cancer Therapy","volume":"2","author":"Scott","year":"2020","journal-title":"Molecules"},{"key":"10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40364-019-0175-x","article-title":"Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia","volume":"7","author":"Liu","year":"2019","journal-title":"Biomark Res"},{"key":"11","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.1182\/blood.V93.11.3678","article-title":"Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate","volume":"9","author":"Bernstein","year":"1999","journal-title":"Blood"},{"key":"12","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1021\/acs.molpharmaceut.8b00225","article-title":"Metabolism of an Oxime-Linked Antibody Drug Conjugate, AGS62P1, and Characterization of Its Identified Metabolite","volume":"1","author":"Mendelsohn","year":"2018","journal-title":"Mol Pharm"},{"key":"13","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1053\/j.seminhematol.2008.07.007","article-title":"Targeting FLT3 for the treatment of leukemia","volume":"4","author":"Small","year":"2008","journal-title":"Semin Hematol"},{"key":"14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"1","author":"Chandarlapaty","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"15","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1182\/blood.V81.11.3091.3091","article-title":"High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy","volume":"8","author":"Guyotat","year":"1993","journal-title":"Blood"},{"key":"16","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia","volume":"6","author":"Kadia","year":"2016","journal-title":"Cancer Discov"},{"key":"17","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1182\/bloodadvances.2018016121","article-title":"Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort","volume":"2","author":"Cluzeau","year":"2018","journal-title":"Blood Adv"},{"key":"18","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.3324\/haematol.2018.188094","article-title":"Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia","volume":"10","author":"Stein","year":"2018","journal-title":"Haematologica"},{"key":"19","doi-asserted-by":"publisher","first-page":"5873","DOI":"10.3390\/ijms22115873","article-title":"FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review","volume":"2","author":"Cluzeau","year":"2021","journal-title":"Int J Mol Sci"},{"key":"20","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1021\/acs.jmedchem.0c01851","article-title":"FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance","volume":"6","author":"Lu","year":"2021","journal-title":"J Med Chem"},{"key":"21","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML","volume":"38","author":"Di Stasi","year":"2019","journal-title":"N Engl J Med"},{"key":"22","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"37","author":"Wei","year":"2017","journal-title":"N Engl J Med"},{"key":"23","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"37","author":"Martincorena","year":"2016","journal-title":"N Engl J Med"},{"key":"24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40364-020-00196-2","article-title":"Advances in targeted therapy for acute myeloid leukemia","volume":"8","author":"Song","year":"2020","journal-title":"Biomark Res"},{"key":"25","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13045-018-0603-7","article-title":"Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells","volume":"1","author":"Wang","year":"2018","journal-title":"J Hematol Oncol"},{"key":"26","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3892\/ijo.2017.4028","article-title":"APG-1252-12A induces mitochondria-dependent apoptosis through inhibiting the antiapoptotic proteins Bcl-2\/Bcl-xl in HL-60 cells","volume":"5","author":"Sun","year":"2017","journal-title":"Int J Oncol"},{"key":"27","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13045-021-01079-1","article-title":"Targeting MCL-1 in cancer: current status and perspectives","volume":"1","author":"Chen","year":"2021","journal-title":"J Hematol Oncol"},{"key":"28","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1002\/cncr.29383","article-title":"New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia","volume":"12","author":"Kantarjian","year":"2015","journal-title":"Cancer"},{"key":"29","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.3892\/mmr.2017.8232","article-title":"High expression of FLT3 is a risk factor in leukemia","volume":"1","author":"Wang","year":"2018","journal-title":"Mol Med Rep"},{"key":"30","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1182\/blood.V87.3.1089.bloodjournal8731089","article-title":"Expression of the hematopoietic growth factor receptor FLT3 (STK-1\/Flk2) in human leukemias","volume":"8","author":"Small","year":"1996","journal-title":"Blood"},{"key":"31","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1182\/bloodadvances.2019001416","article-title":"Cotargeting BCL-2 and MCL-1 in high-risk B-ALL","volume":"4","author":"Schoumacher","year":"2020","journal-title":"Blood Adv"},{"key":"32","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma","volume":"1","author":"Opferman","year":"2021","journal-title":"Cancer Discov"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28331","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T13:42:09Z","timestamp":1671543729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,20]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12,20]]}},"alternative-id":["28331"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28331","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,20]]}}}